Keytruda (pembrolizumab) demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; p=0.0010) as a potential adjuvant treatment of renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.
A study found that PD-L1, PD-L2 and tumor mutation burden from a comprehensive genomic and transcriptomic profiling test independently predicted Keytruda (pembrolizumab) benefit in pan-solid tumors—and when combined in a multivariate signature score—predicted benefit better than PD-L1 or TMB alone.
The phase III TULIP study met its primary endpoint of progression-free survival in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer—demonstrating a statistically significant improvement over physician’s choice.
The likelihood of prostate cancer surgery for patients presenting for treatment across Pennsylvania declined among Black patients, but not white patients, during the initial wave of the COVID-19 pandemic, according to new research from Fox Chase Cancer Center.
Roswell Park Comprehensive Cancer Center researchers found that an opioid-restricting protocol resulted in a 45% decrease in the amount of opioids prescribed, without any significant effect on patient recovery or satisfaction.
Researchers found that treatment with immune checkpoint inhibitors has led to a significant improvement in survival and response rates in advanced sarcomatoid renal cell carcinoma.
A study led by researchers at Yale Cancer Center, Stony Brook University and KDx Diagnostics, Inc., examined a new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.
Results from the interventional PATHFINDER study evaluating Galleri, a multi-cancer early detection (MCED) blood test, show that the blood test can detect cancers before symptoms arise.
A phase II clinical trial evaluating a personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma, demonstrated a 42% reduction in risk of disease progression or death at 6.9 months.
The myCare-022-03 study demonstrated that the Cellworks Singulaä Therapy Response Index is strongly predictive of overall survival and disease-free survival for glioblastoma patients.
